Abstract
Safety is usually a secondary endpoint in clinical trials, and most observational studies on predictors focus on response, not toxicity. Research is clearly biased towards efficacy rather than safety, probably because of the difficulty in measuring toxicity arising from lack of standardization, low statistical power, missing data, misinterpretation, and confounding variables. An extensive search revealed very few studies on toxicity markers for the drugs used to treat rheumatoid arthritis. The literature contains many studies on predictors of the safety of methotrexate. Most analyze genetic markers, which are difficult to apply in daily practice. We found few studies on markers of toxicity for biologics. As many adverse events are related to patient characteristics, we recommend that clinicians understand the risk factors for the most common adverse events, especially infections and cancer, and manage risk on an individual basis. Moreover, patient involvement in monitoring safety is crucial.
Keywords: Rheumatoid arthritis, adverse effects, toxicity, safety.
Current Pharmaceutical Design
Title:Predicting Toxicity: Biomarkers and the Value of the Patient's Opinion
Volume: 21 Issue: 2
Author(s): MJ Garcia de Yebenes, E Loza and L Carmona
Affiliation:
Keywords: Rheumatoid arthritis, adverse effects, toxicity, safety.
Abstract: Safety is usually a secondary endpoint in clinical trials, and most observational studies on predictors focus on response, not toxicity. Research is clearly biased towards efficacy rather than safety, probably because of the difficulty in measuring toxicity arising from lack of standardization, low statistical power, missing data, misinterpretation, and confounding variables. An extensive search revealed very few studies on toxicity markers for the drugs used to treat rheumatoid arthritis. The literature contains many studies on predictors of the safety of methotrexate. Most analyze genetic markers, which are difficult to apply in daily practice. We found few studies on markers of toxicity for biologics. As many adverse events are related to patient characteristics, we recommend that clinicians understand the risk factors for the most common adverse events, especially infections and cancer, and manage risk on an individual basis. Moreover, patient involvement in monitoring safety is crucial.
Export Options
About this article
Cite this article as:
Yebenes Garcia de MJ, Loza E and Carmona L, Predicting Toxicity: Biomarkers and the Value of the Patient's Opinion, Current Pharmaceutical Design 2015; 21 (2) . https://dx.doi.org/10.2174/1381612820666140825124352
DOI https://dx.doi.org/10.2174/1381612820666140825124352 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting of Antioxidant and Anti-Thrombotic Drugs to Endothelial Cell Adhesion Molecules
Current Pharmaceutical Design Disease Modification in Rheumatoid Arthritis and Osteoarthritis-Current and Emerging Targets and Therapeutics
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Synthesis and Biological Activity of a New Class of Azetidinones Compounds as Potential HLE Inhibitors
Letters in Drug Design & Discovery pH Modulation Based Solid Dispersion to Enhance Solubility of a Poorly Soluble NSAID - Development and Evaluation
Drug Delivery Letters De-Risking Bio-therapeutics for Possible Drug Interactions Using Cryopreserved Human Hepatocytes
Current Drug Metabolism It is All About Proteases: From Drug Delivery to In Vivo Imaging and Photomedicine
Current Medicinal Chemistry Advances in Encoding of Colloids for Combinatorial Libraries: Applications in Genomics, Proteomics and Drug Discovery
Current Pharmaceutical Biotechnology Preface:
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Contrasting Roles of the Galectin-3 in the Schizophrenia Onset, Clinical Presentation, and Somatic Comorbidity
Current Topics in Medicinal Chemistry Evolutioninthe Pharmacogenetics and Pharmacogenomics of Inflammatory Bowel Disease - Order Slowly Rises from the Chaos
Current Pharmacogenomics Pediatric Immune Dysfunction and Health Risks Following Early-Life Immune Insult
Current Pediatric Reviews Identification of the Active Constituents and Significant Pathways of Guizhi-Shaoyao-Zhimu Decoction for the Treatment of Diabetes Mellitus Based on Molecular Docking and Network Pharmacology
Combinatorial Chemistry & High Throughput Screening Cell Therapies for IBD: What Works?
Current Drug Targets Polymer Drug Conjugates: Recent Advancements in Various Diseases
Current Pharmaceutical Design New Organ-Specific Pharmacological Strategies Interfering With Signaling Pathways In Inflammatory Disorders/Autoimmune Disorders
Current Signal Transduction Therapy Chemokines and Chemokine Receptors Blockers as New Drugs for the Treatment of Chronic Obstructive Pulmonary Disease
Current Medicinal Chemistry Triterpenoids for Cancer Prevention and Treatment: Current Status and Future Prospects
Current Pharmaceutical Biotechnology Glucocorticoids and their Effects on Bone and Joints in Rheumatoid Arthritis
Current Rheumatology Reviews Glyco-Nanomaterials: Translating Insights from the “Sugar-Code” to Biomedical Applications
Current Medicinal Chemistry Integrin α4β7 Antagonists: Activities, Mechanisms of Action and Therapeutic Prospects
Current Immunology Reviews (Discontinued)